Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 15-Aug-23 4:15 PM View:  | Flagship Ventures Fund V Ge... 10% Owner | Sigilon Therapeutics, Inc. (SGTX) | 11-Aug-23 | Disposition (change in control) | 797,720 | $14.92 | $11,902,000.00 | (100%) 797.72K to 0 | |
| 11-Aug-23 4:10 PM View: | Pontes Josias CHIEF FINANCIAL OFFICER | Sigilon Therapeutics, Inc. (SGTX) | 11-Aug-23 | Disposition | 3,504 | -- | -- | (100%) 3.5K to 0 | |
| 11-Aug-23 4:10 PM View: | Kowalsky Matthew Paul CHIEF OF STAFF AND CLO | Sigilon Therapeutics, Inc. (SGTX) | 11-Aug-23 | Disposition | 1,925 | -- | -- | (100%) 1.93K to 0 | |
| 11-Aug-23 4:10 PM View: | Vivaldi Coelho Rogerio President and CEO Director | Sigilon Therapeutics, Inc. (SGTX) | 11-Aug-23 | Disposition | 12,169 | -- | -- | (100%) 12.17K to 0 | |
| 11-Aug-23 4:10 PM View: | Cox John Director | Sigilon Therapeutics, Inc. (SGTX) | 11-Aug-23 | Disposition | 341 | -- | -- | (100%) 0.34K to 0 | |
| 11-Aug-23 4:10 PM View: | Yuan Qing Sarah CTOO | Sigilon Therapeutics, Inc. (SGTX) | 11-Aug-23 | Disposition | 2,884 | -- | -- | (100%) 2.88K to 0 | |
| 27-Jul-23 4:21 PM View: | Yuan Qing Sarah CTOO | Sigilon Therapeutics, Inc. (SGTX) | 27-Jul-23 | Option Exercise | 2,884 | $19.24 | $55,488.20 | 100% 0 to 2.88K | |
| 24-Jul-23 7:44 PM View: | Vivaldi Coelho Rogerio President and CEO Director | Sigilon Therapeutics, Inc. (SGTX) | 21-Jul-23 | Option Exercise | 5,528 | $19.24 | $106,359.00 | 86% 6.43K to 11.96K | |
| 24-Jul-23 7:45 PM View: | Pontes Josias CHIEF FINANCIAL OFFICER | Sigilon Therapeutics, Inc. (SGTX) | 21-Jul-23 | Option Exercise | 1,444 | $19.24 | $27,782.60 | 80% 1.81K to 3.25K | |
| 05-Nov-21 4:15 PM View: | Vivaldi Coelho Rogerio President and CEO Director | Sigilon Therapeutics, Inc. (SGTX) | 04-Nov-21 | Grant | 50,000 | -- | -- | 213% 23.46K to 73.46K | |
| 04-Oct-21 4:15 PM View: | Pontes Josias VP, Head of Finance | Sigilon Therapeutics, Inc. (SGTX) | 30-Sep-21 | Grant | 11,500 | -- | -- | 625% 1.84K to 13.34K | |
| 04-Jun-21 4:15 PM View: | Anderson Daniel Griffith Director | Sigilon Therapeutics, Inc. (SGTX) | 02-Jun-21 | Market Sale | 200,000 | $10.00 | $2,000,000.00 | (9%) 2.22M to 2.02M | (7%) |
| 10-Dec-20 6:15 PM View: | Cox John Director | Sigilon Therapeutics, Inc. (SGTX) | 08-Dec-20 | Conversion | 4,444 | -- | -- | 100% 0 to 4.44K | |
| 10-Dec-20 5:00 PM View: | Lilly Eli & Co 10% Owner | Sigilon Therapeutics, Inc. (SGTX) | 08-Dec-20 | Conversion | 2,444,440 | -- | -- | 100% 0 to 2.44M | |
| 10-Dec-20 6:19 PM View: | Flagship Ventures Fund V Ge... 10% Owner | Sigilon Therapeutics, Inc. (SGTX) | 08-Dec-20 | Conversion | 10,370,400 | -- | -- | 100% 0 to 10.37M | |
| 10-Dec-20 6:13 PM View: | Vivaldi Coelho Rogerio President and CEO Director | Sigilon Therapeutics, Inc. (SGTX) | 08-Dec-20 | Conversion | 22,222 | -- | -- | 100% 0 to 22.22K | |
| 10-Dec-20 5:00 PM View: | Lilly Eli & Co 10% Owner | Sigilon Therapeutics, Inc. (SGTX) | 08-Dec-20 | Purchase | 300,000 | $18.00 | $5,400,000.00 | 12% 2.44M to 2.74M |
